Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for INLYTA
- Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
- Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations Independent of HER2 Expression With Progression After Previous Treatment
- Phase II Study of Axitinib Intensification Plus Nivolumab Compared to Nivolumab Alone After Induction With Nivolumab Plus Ipilimumab in mRCC Patients Without Previous CR
- A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
- Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study
- Avelumab, Palbociclib and Axitinib in Advanced RCC
- Axitinib + Ipilimumab in Advanced Melanoma
- Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma
- A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer
- Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread
- Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma
- Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma
- Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery
- ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
- Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma
- Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
- Avelumab With Axitinib in Persistent or Recurrent Cervical Cancer After Platinum-based Chemotherapy
- A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
- Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous Invasion
- Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis
- A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
- Prior Axitinib as a Determinant of Outcome of Renal Surgery
- Survival Prolongation by Rationale Innovative Genomics
- Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
- The Drug Rediscovery Protocol (DRUP Trial)
- Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma
- Axitinib in R/M Salivary Gland Cancers of the Upper Aerodigestive Tract - SGC-AX14
- The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCC
- Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia
- Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
- Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
- Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas
- Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
- Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma
- Phase II Study on Axitinib in Advanced Solitary Fibrous Tumor
- VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors
- Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea
- Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
- Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
- Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma
- Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
- Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients
- Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery
- Study of Axitinib and Temsirolimus in Solid Tumors
- Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis
- Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
- Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]
Clinical trials list
click for details